Current approach in diagnosis and management of anterior uveitis.
Uveitis is composed of a diverse group of disease entities, which in total has been estimated to cause approximately 10% of blindness. Uveitis is broadly classified into anterior, intermediate, posterior and panuveitis based on the anatomical involvement of the eye. Anterior uveitis is, however, the commonest form of uveitis with varying incidences reported in worldwide literature. Anterior uveitis can be very benign to present with but often can lead to severe morbidity if not treated appropriately. The present article will assist ophthalmologists in accurately diagnosing anterior uveitis, improving the quality of care rendered to patients with anterior uveitis, minimizing the adverse effects of anterior uveitis, developing a decision-making strategy for management of patients at risk of permanent visual loss from anterior uveitis, informing and educating patients and other healthcare practitioners about the visual complications, risk factors, and treatment options associated with anterior uveitis.
Agrawal
Rupesh V
RV
L. V. Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, India.
Murthy
Somasheila
S
Sangwan
Virender
V
Biswas
Jyotirmay
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000150:complications; D003937:Diagnosis, Differential; D005451:Fluorescein Angiography / Q000379:methods*; D005654:Fundus Oculi; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015863:Iridocyclitis / Q000150:complications; D007910:Lenses, Intraocular / Q000009:adverse effects; D033401:Microscopy, Acoustic / Q000379:methods*; D011379:Prognosis; D041623:Tomography, Optical Coherence / Q000379:methods*; D014606:Uveitis, Anterior / Q000175:diagnosis / Q000209:etiology / Q000628:therapy
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents